Answers are grounded in this paper and cite their sources.
The genetic etiology of Type 2 Diabetes (T2D) involves regulatory mechanisms operating across multiple metabolic tissues. However, candidate effector gene prioritization can be limited by approaches that focus predominantly on pancreatic transcriptomics. To address this limitation, we developed CAS-X, a computational multi-tissue functional genomics framework for prioritizing candidate effector genes at T2D susceptibility loci. CAS-X integrates fine-mapped Posterior Inclusion Probabilities (PIP) and allelic fold changes (aFC) across five tissues: pancreas, skeletal muscle, subcutaneous adipose, visceral adipose, and whole blood. In the reported analysis, multi-tissue integration identified 28 candidate genes meeting the selected prioritization threshold, compared with 12 under the pancreas-only baseline, representing a 133.3% increase in candidate coverage. Prioritized candidates included JAZF1, FTO, GRB14, and CDKN2B. Framework robustness was examined through Leave-One-Tissue-Out sensitivity analysis and comparisons with non-metabolic GTEx Brain Cortex controls. Pathway enrichment analysis highlighted associations with insulin resistance, adipocytokine signaling, and lipolysis regulation. The analysis also incorporated phenome-wide associations and computational assessments of therapeutic tractability. CAS-X provides a computational approach for integrating regulatory evidence across metabolic tissues to support candidate effector gene prioritization in T2D research.
No takes yet. Share an insight, caveat, or question.
Uddin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: